Ondansetron-medication used to prevent nausea and vomiting caused by cancer chemotherapy, radiation therapy etc

Ondansetron is used to prevent nausea and vomiting that is caused by cancer medicines (chemotherapy) or radiation therapy.

Ondansetron-medication used to prevent nausea and vomiting caused by cancer chemotherapy, radiation therapy etc

Ondansetron; Zofran; Zophren; Zudan

A-Tron, Adom-O, Afon, Altitron, Ansecare, Anset, Astadon-MD, Back2Norm, Bludan, Bond, C-Tron, Chew-It, Danset, Dasin, Dentron, Divitron, Doin, Domi-Up, Donset, Donsetron, Doran-O, Doran-O INJ, Dotson, Dutron, E-On, Edeset, Eldon, Emecule, Emefilm, Emeran, Emeset, Emeset SYR, Emestal-O, Emestop, Emetron, Emigo, Emiof, Emitino, Emitron, Emitus, Emnil, Emsetron, Emstal, Emtron, Emtron-MD, Flatron, Flexi, Fodino, Gendem-Md, Glendan

9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-2,3,4,9-tetrahydro-1H-carbazol-4-one

Ondansetron is a selective serotonin 5-HT₃ receptor antagonist. The antiemetic activity of the drug is due to the inhibition of 5-HT₃ receptors present on both peripherally (GI tract) and centrally (medullary chemoreceptor zone). This inhibition of 5-HT₃ receptors in turn inhibits the visceral afferent stimulation of the vomiting center, likely indirectly at the level of the area postrema, as well as through direct inhibition of serotonin activity within the the chemoreceptor trigger zone and area postrema.

Used as an antiemetic to treat nausea and vomiting following chemotherapy.

Headache, malaise/fatigue, constipation; drowsiness, fever, dizziness, anxiety, cold sensation; pruritus, rash; diarrhoea; gynaecological disorder, urinary retention; elevated transaminase; local inj site reaction (pain, redness, burning); paresthesia; hypoxia. Rarely: Anaphylaxis, angina, bronchospasm, ECG changes, extrapyramidal symptoms, grand mal seizure, hypokalaemia, tachycardia, vascular occlusive events.

• Avoid concurrent use. Concurrent use may increase the hypotensive effect of apomorphine
• Rifampicin and other CYP3A4 inducers reduce levels/effects of ondansetron.

Concomitant use of apomorphine with ondansetron is contraindicated.

Store at 2-30°C

Molecular weight

293.363

Molecular formula

C18H19N3O

CAS number

99614-02-5

Precautions

May cause QT prolongation; caution when used in cardiac diseases, patients who are on medications that can prolong QT or patients with electrolyte abnormalities. Severe hepatic impairment. May mask progressive ileus and/or gastric distension. Pregnancy, lactation.